RT Journal Article
SR Electronic
T1 COVID-19 herd immunity in the Brazilian Amazon
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.16.20194787
DO 10.1101/2020.09.16.20194787
A1 Lewis F Buss
A1 Carlos A Prete, Jr
A1 Claudia MM Abrahim
A1 Alfredo Mendrone, Jr
A1 Tassila Salomon
A1 Cesar de Almeida-Neto
A1 Rafael FO França
A1 Maria C Belotti
A1 Maria PSS Carvalho
A1 Allyson G Costa
A1 Myuki AE Crispim
A1 Suzete C Ferreira
A1 Nelson A Fraiji
A1 Susie Gurzenda
A1 Charles Whittaker
A1 Leonardo T Kamaura
A1 Pedro L Takecian
A1 Marcio K Oikawa
A1 Anna S Nishiya
A1 Vanderson Rocha
A1 Nanci A Salles
A1 Andreza A de Souza-Santos
A1 Martirene A da Silva
A1 Brian Custer
A1 Manoel Barral-Netto
A1 Moritz UG Kraemer
A1 Rafael HM Pereira
A1 Oliver G Pybus
A1 Michael P Busch
A1 Márcia C Castro
A1 Christopher Dye
A1 Vitor H Nascimento
A1 Nuno R Faria
A1 Ester C Sabino
YR 2020
UL http://medrxiv.org/content/early/2020/09/21/2020.09.16.20194787.abstract
AB The herd immunity threshold is the proportion of a population that must be immune to an infectious disease, either by natural infection or vaccination such that, in the absence of additional preventative measures, new cases decline and the effective reproduction number falls below unity1. This fundamental epidemiological parameter is still unknown for the recently-emerged COVID-19, and mathematical models have predicted very divergent results2,3. Population studies using antibody testing to infer total cumulative infections can provide empirical evidence of the level of population immunity in severely affected areas. Here we show that the transmission of SARS-CoV-2 in Manaus, located in the Brazilian Amazon, increased quickly during March and April and declined more slowly from May to September. In June, one month following the epidemic peak, 44% of the population was seropositive for SARS-CoV-2, equating to a cumulative incidence of 52%, after correcting for the false-negative rate of the antibody test. The seroprevalence fell in July and August due to antibody waning. After correcting for this, we estimate a final epidemic size of 66%. Although non-pharmaceutical interventions, plus a change in population behavior, may have helped to limit SARS-CoV-2 transmission in Manaus, the unusually high infection rate suggests that herd immunity played a significant role in determining the size of the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Itau Unibanco Todos pela Saude program and CADDE/FAPESP (MR/S0195/1 and FAPESP 18/14389-0). NRF is supported by the Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z). We acknowledge the National Heart, Lung, and Blood Institute of the US National Institutes of Health Recipient Epidemiology and Donor Evaluation Study (REDS, now in its 4th phase, REDS-IV-P) for providing the blood donor demographic and zip code data for analysis (grant number HHSN268201100007I). This work received funding from the U.K. Medical Research Council under a concordat with the U.K. Department for International Development. We additionally acknowledge support from Community Jameel and the NIHR Health Protection Research Unit in Modelling Methodology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Brazilian national research ethics committee, CONEP CAAE - 30178220.3.1001.0068.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data required to reproduce the results in this article will be deposited on the Figshare repository upon acceptance of the article (URL), where the raw data underlying the main figures will be provided. Also, upon acceptance, the custom code will be made available at the linked GitHub repository (URL).